Currently, a phase II clinical trial of a TLR7 antagonist (NCT04448756) is being completed, which investigated the antagonist’s possibilities in modulating the CS and immunopathology in severe COVID-19 patients. This evidence concerns the gene TLR7 and COVID-19.